BIO-TECHNE HIGHLIGHTS RECENTLY ANNOUNCED TOP-LINE BIOMARKER DATA FROM PARTNER, REGULUS THERAPEUTICS, USING THE COMPANY’S PROPRIETARY TECHNOLOGY

May 22, 2024

https://www.prnewswire.com/news-releases/bio-techne-highlights-recently-announced-top-line-biomarker-data-from-partner-regulus-therapeutics-using-the-companys-proprietary-technology-302152199.html

MINNEAPOLIS, May 22, 2024 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced continued technical and clinical collaboration following release of Regulus’ positive topline results from the second cohort of patients in its Phase 1b MAD (multiple ascending dose) study of RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The two companies began the collaboration in 2020 to support Regulus’ biomarker analysis for the clinical development of anti-miR-17 therapies for ADPKD treatment.

Read more at prnewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.